Molecular pathogenesis, mechanism and therapy of Cav1 in prostate cancer

Bian, Qiang; Li, Bei; Zhang, Luting; Sun, Yinuo; Zhao, Zhankui; Ding, Yi; Yu, Honglian

doi:10.1007/s12672-023-00813-0

Cited by 3 publications

(2 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Abnormal Cav1 expression leads to faster progression of prostate cancer and is not conducive to treatment. [27] The above literature review is consistent with our results, and based on above literature analysis, we speculate that CAV1 may play an important role in occurrence and development of prostate cancer, but its mechanism of action on prostate cancer needs to be further explored.…”

Section: Discussionsupporting

confidence: 90%

CAV1 and KRT5 are potential targets for prostate cancer

Guo,

Liu,

Yang

et al. 2023

Medicine

View full text Add to dashboard Cite

Prostate cancer is the most common malignant tumor of male urogenital system that occurs in prostate epithelium. However, relationship between CAV1 and KRT5 and prostate cancer remains unclear. The prostate cancer datasets GSE114740 and GSE200879 were downloaded from Gene Expression Omnibus generated by GPL11154 and GPL32170. De-batch processing was performed, differentially expressed genes (DEGs) were screened, and weighted gene co-expression network analysis. The construction and analysis of protein–protein interaction network, functional enrichment analysis, gene set enrichment analysis. Gene expression heat map was drawn and immune infiltration analysis was performed. Comparative toxicogenomics database analysis were performed to find the disease most related to core gene. In addition, the cell experiment was performed to verify the role of CAV1 and KRT5 by western blot. Divided into 4 groups: control, prostate cancer, prostate cancer-over expression, and prostate cancer- knock out. TargetScan screened miRNAs that regulated central DEGs; 770 DEGs were identified. According to Gene Ontology analysis, they were mainly concentrated in actin binding and G protein coupled receptor binding. In Kyoto Encyclopedia of Gene and Genome analysis, they were mainly concentrated in PI3K-Akt signal pathway, MAPK signal pathway, and ErbB signal pathway. The intersection of enrichment terms of differentially expressed genes and GOKEGG enrichment terms was mainly concentrated in ErbB signaling pathway and MAPK signaling pathway. Three important modules were generated. The protein–protein interaction network obtained 8 core genes (CAV1, BDNF, TGFB3, FGFR1, PRKCA, DLG4, SNAI2, KRT5). Heat map of gene expression showed that core genes (CAV1, TGFB3, FGFR1, SNAI2, KRT5) are highly expressed in prostate cancer tissues and low in normal tissues. Comparative toxicogenomics database analysis showed that core genes (CAV1, TGFB3, FGFR1, SNAI2, KRT5) were associated with prostate tumor, cancer, tumor metastasis, necrosis, and inflammation. CAV1 and KRT5 are up-regulated in prostate cancer. CAV1 and KRT5 are highly expressed in prostate cancer. The higher expression of CAV1 and KRT5, the worse prognosis.

show abstract

Section: Discussionsupporting

confidence: 90%

CAV1 and KRT5 are potential targets for prostate cancer

Guo,

Liu,

Yang

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…On the other hand, the silencing of MCT-4 impaired the maturation and trafficking of CD147 to the cell surface, resulting in the accumulation of CD147 in the endoplasmic reticulum [49]. Recent studies revealed the involvement of CD147 in cancer cell glycolysis in various malignant tumors including non-small-cell lung cancer, hepatocellular carcinoma, colorectal cancer, prostate cancer, and anaplastic large-cell lymphoma [50][51][52][53][54][55]. These findings strongly suggest that CD147 interacts with MCT-1 and MCT-4 to promote glycolysis in tumor cells, resulting in tumor progression (Figure 2).…”

Section: Cd147 In Cancer Cell Glycolysismentioning

confidence: 99%

CD147/Basigin Is Involved in the Development of Malignant Tumors and T-Cell-Mediated Immunological Disorders via Regulation of Glycolysis

Kanekura

2023

IJMS

View full text Add to dashboard Cite

CD147/Basigin, a transmembrane glycoprotein belonging to the immunoglobulin superfamily, is a multifunctional molecule with various binding partners. CD147 binds to monocarboxylate transporters (MCTs) and supports their expression on plasma membranes. MTC-1 and MCT-4 export the lactic acid that is converted from pyruvate in glycolysis to maintain the intracellular pH level and a stable metabolic state. Under physiological conditions, cellular energy production is induced by mitochondrial oxidative phosphorylation. Glycolysis usually occurs under anaerobic conditions, whereas cancer cells depend on glycolysis under aerobic conditions. T cells also require glycolysis for differentiation, proliferation, and activation. Human malignant melanoma cells expressed higher levels of MCT-1 and MCT-4, co-localized with CD147 on the plasma membrane, and showed an increased glycolysis rate compared to normal human melanocytes. CD147 silencing by siRNA abrogated MCT-1 and MCT-4 membrane expression and disrupted glycolysis, inhibiting cancer cell activity. Furthermore, CD147 is involved in psoriasis. MCT-1 was absent on CD4+ T cells in CD147-deficient mice. The naïve CD4+ T cells from CD147-deficient mice exhibited a low capacity to differentiate into Th17 cells. Imiquimod-induced skin inflammation was significantly milder in the CD147-deficient mice than in the wild-type mice. Overall, CD147/Basigin is involved in the development of malignant tumors and T-cell-mediated immunological disorders via glycolysis regulation.

show abstract

Cell Membrane‐Camouflaged Chitosan‐Polypyrrole Nanogels Co‐Deliver Drug and Gene for Targeted Chemotherapy and Bone Metastasis Inhibition of Prostate Cancer

Yu,

Gao,

Dai

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

The development of functional nanoplatforms to improve the chemotherapy outcome and inhibit distal cancer cell metastasis remains an extreme challenge in cancer management. In this work, we report a human‐derived PC‐3 cancer cell membrane‐camouflaged chitosan‐polypyrrole nanogel (CH‐PPy NG) platform, which can be loaded with chemotherapeutic drug docetaxel (DTX) and RANK siRNA for targeted chemotherapy and gene silencing‐mediated metastasis inhibition of late‐stage prostate cancer in a mouse model. The prepared NGs with a size of 155.8 nm show good biocompatibility, pH‐responsive drug release profile, and homologous targeting specificity to cancer cells, allowing for efficient and precise drug/gene co‐delivery. Through in‐vivo antitumor treatment in a xenografted PC‐3 mouse tumor model, we show that such a CH‐PPy NG‐facilitated co‐delivery system allows for effective chemotherapy to slow down the tumor growth rate, and effectively inhibits the metastasis of prostate cancer to the bone via downregulation of the RANK/RANKL signaling pathway. The created CH‐PPy NGs may be utilized as a promising platform for enhanced chemotherapy and anti‐metastasis treatment of prostate cancer.This article is protected by copyright. All rights reserved

show abstract

Molecular pathogenesis, mechanism and therapy of Cav1 in prostate cancer

Cited by 3 publications

References 121 publications

CAV1 and KRT5 are potential targets for prostate cancer

CAV1 and KRT5 are potential targets for prostate cancer

CD147/Basigin Is Involved in the Development of Malignant Tumors and T-Cell-Mediated Immunological Disorders via Regulation of Glycolysis

Cell Membrane‐Camouflaged Chitosan‐Polypyrrole Nanogels Co‐Deliver Drug and Gene for Targeted Chemotherapy and Bone Metastasis Inhibition of Prostate Cancer

Contact Info

Product

Resources

About